MORGAN STANLEY - MERRIMACK PHARMACEUTICALS IN ownership

MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 65 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.4%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of MERRIMACK PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,148,873
+13.0%
93,177
+12.7%
0.00%
Q2 2023$1,017,026
+52.8%
82,685
+52.7%
0.00%
Q1 2023$665,627
+533.9%
54,160
+491.1%
0.00%
Q4 2022$105,009
+320.0%
9,163
+40.7%
0.00%
Q3 2022$25,000
-41.9%
6,514
-11.5%
0.00%
Q2 2022$43,000
+10.3%
7,358
+20.2%
0.00%
Q1 2022$39,000
+105.3%
6,123
+19.5%
0.00%
Q4 2021$19,000
-32.1%
5,122
-12.1%
0.00%
Q3 2021$28,000
-61.1%
5,828
-47.8%
0.00%
Q2 2021$72,000
+89.5%
11,161
+87.8%
0.00%
Q1 2021$38,000
+11.8%
5,943
+17.4%
0.00%
Q4 2020$34,000
+126.7%
5,063
+32.1%
0.00%
Q3 2020$15,000
+25.0%
3,832
+10.3%
0.00%
Q2 2020$12,000
-29.4%
3,475
-56.0%
0.00%
Q1 2020$17,000
-50.0%
7,903
-26.6%
0.00%
Q4 2019$34,000
-76.7%
10,766
-66.7%
0.00%
Q3 2019$146,000
+256.1%
32,372
+385.5%
0.00%
Q2 2019$41,000
-25.5%
6,668
-16.0%
0.00%
Q1 2019$55,000
+83.3%
7,936
+1.9%
0.00%
Q4 2018$30,000
-65.1%
7,790
-51.3%
0.00%
Q3 2018$86,000
-73.2%
15,992
-75.5%
0.00%
Q2 2018$321,000
+4.6%
65,405
+71.1%
0.00%
Q1 2018$307,000
-12.8%
38,218
+11.3%
0.00%
Q4 2017$352,000
-10.4%
34,350
+26.9%
0.00%
Q3 2017$393,00027,0620.00%
Other shareholders
MERRIMACK PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Newtyn Management, LLC 362,335$3,714,0000.57%
Rubric Capital Management LP 410,244$4,205,0000.52%
WITTENBERG INVESTMENT MANAGEMENT, INC. 83,811$859,0000.37%
Yakira Capital Management, Inc. 83,969$861,0000.28%
KEMPNER CAPITAL MANAGEMENT INC. 14,898$153,0000.10%
STONEBRIDGE CAPITAL MANAGEMENT INC 18,550$200,0000.07%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 66,498$681,0000.05%
Cannell & Co. 75,467$774,0000.03%
Trexquant Investment LP 21,347$219,0000.02%
PDT Partners, LLC 58,004$595,0000.02%
View complete list of MERRIMACK PHARMACEUTICALS IN shareholders